Table 1.
Clinico-pathological characteristics of patients, FAS population (n = 502).
| Variable | n (%) |
|---|---|
| Sex, n (%) | |
| Male | 414 (82.5) |
| Female | 88 (17.5) |
| Age, years * | 69.6 ± 10.6 (34–94) |
| BMI, kg/m2 * | 3.4 ± 1.3 (1–6) |
| Smoking status, n (%) | |
| Non-smoker | 92 (18.3) |
| Ex-smoker | 256 (51) |
| Current smoker | 128 (25.5) |
| Unknown | 26 (5.2) |
| Number of tumors, n (%) (#) | |
| Single | 258 (52.4) |
| Multiple | 234 (47.6) |
| Tumor size, n (%) (#) | |
| <3 cm | 333 (67.7) |
| ≥3 cm | 159 (32.3) |
| Pathological stage, n (%) | |
| Ta | 376 (74.9) |
| T1 | 116 (23.1) |
| Primary carcinoma in situ | 10 (2) |
| Grade (##), n (%) | |
| G1 | 173 (34.45) |
| G2 | 178 (35.45) |
| G3 | 151 (30.1) |
| EAU Risk stratification, n (%) | |
| Intermediate-risk | 297 (59.2) |
| High-risk | 205 (40.8) |
| Previous treatment with MMC, n (%) | 69 (13.7) |
| Previous treatment with BCG, n (%) | 51 (10.15) |
| Follow-up, months * | 24.45 ± 16.5 (1–81) |
| Recurrence during follow-up, n (%) | 159 (31.7) |
| Progression during follow-up, n (%) | 35 (7) |
| Overall mortality, during follow-up (%) | 66 (13.15) |
* Values expressed in mean ± SD (range); BMI, body mass index; (#) excluding carcinoma in situ; (##), Grade according to WHO; MMC, mitomycin; BCG, bacillus Calmette-Guérin.